Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 13 years
- Director since
- 2023
13 years of board service in total across 4 boards, counting each seat separately. Longest: AnaptysBio Inc., 3 years.
AnaptysBio Inc.
Director
Design Therapeutics Inc.
Director
Xeris Biopharma Holdings Inc.
Director
BridgeBio Oncology Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 12, 2024 | Xeris Biopharma Holdings Inc. | Open-market purchase | +4,515 | $2.25 | $10,159 |
| Aug 9, 2024 | Xeris Biopharma Holdings Inc. | Open-market purchase | +4,285 | $2.37 | $10,155 |
| Jun 15, 2024 | AnaptysBio Inc. | Option exercise | +3,900 | — | — |
| Jun 5, 2024 | Xeris Biopharma Holdings Inc. | Grant or award | +50,000 | — | — |
| May 10, 2024 | Xeris Biopharma Holdings Inc. | Open-market purchase | +5,400 | $1.91 | $10,314 |
| Mar 25, 2024 | Design Therapeutics Inc. | Open-market purchase | +17,809 | $3.74 | $66,606 |
| Mar 22, 2024 | Design Therapeutics Inc. | Open-market purchase | +9,156 | $3.62 | $33,145 |
| Mar 14, 2024 | Xeris Biopharma Holdings Inc. | Open-market purchase | +4,500 | $2.16 | $9,720 |
| Nov 16, 2023 | Xeris Biopharma Holdings Inc. | Open-market purchase | +6,500 | $1.51 | $9,815 |
| Jun 7, 2023 | Xeris Biopharma Holdings Inc. | Grant or award | +42,500 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.